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(N = 2000) and a test set (N = 4486). A proportion of glucose
and HbA1c specimens were mismatched by randomly switching
either HbA1c or glucose results. The outcome of interest was
correct classiﬁcation of vials as either ‘matched’ or ‘mismatched’.
The outcome was predicted using a Bayesian network that
encoded probabilistic relationships among analytes, self-reported
diabetes status and a latent ‘mismatch’ variable. Performance
was compared against an established approach LabRespond via
area under the receiver-operating characteristics curves (AUCs).
An AUC = 1.0 and 0.5 represents perfect prediction and random
guessing respectively. RESULTS: The network was predictive of
glucose and HbA1c mismatches that produced 20 mg/dL glucose
and 1 point HbA1c discrepancies between true and mismatched
scores (AUC = 0.84 (+/-0.03)). The network also identiﬁed
errors among those self-reporting diabetes (N = 329) AUC =
0.81 (+/-0.02) and predicted self-report of diabetes diagnosis
AUC = 0.95 (+/-0.01). The network also performed better
(z = 12.04, p < 0.001) than LabRespond (AUC = 0.76 +/- 0.01).
CONCLUSION: A Bayesian network that models probabilistic
relationships among analyte values can accurately identify mis-
matched specimens. The algorithm is best at identifying mis-
matches that result in a clinically signiﬁcant magnitude of error.
Information about diabetes diagnosis acted to reduce uncertainty
in a mismatch. Decision analysis may be have direct application
in reducing cost at point-of-care.
PDB80
REDUCING COSTS AND IMPROVING OUTCOMES BY
REDUCING MEDICAL ERRORS:A COMPARISON OF EXPERTS
WITH PROBABLISTIC LABORATORY ERROR DETECTION IN A
POPULATION OF PRE-DIABETICS
Doctor JN1, Strylewicz G2
1University of Southern California, Los Angeles, CA, USA, 2University
of Washington, Seattle,WA, USA
OBJECTIVE: Human evaluation of laboratory errors is a costly
standard of practice. Automating error detection may reduce
costs and improve patient outcomes. To compare an automated
probabilistic approach (Bayesian network) to human expert
error detection in a pre-diabetic population. METHODS: Two
test sets (A and B) each N = 60 were generated from the results
of the Diabetes Prevention Program (DPP). Glucose values
were randomly drawn from a pre-diabetic distribution and
expected HbA1c score was estimated by the DPP based formula:
HbA1c = 4.22 + 0.1604 ¥ Glucose. In each test set, 37% of the
HbA1c scores were mismatched to generate vial labeling errors.
Eleven experts recruited from the American Academy of Clinical
Chemists and a Bayesian network evaluated the results to detect
mismatched vials. Six and ﬁve experts were assigned to test sets
A and B respectively. Receiver-Operating Characteristics (ROC)
curves were generated for each expert and for the Bayesian
network and area under the curves (AUCs) were compared via
null hypothesis testing. An AUC = 1 and 0.5 represents perfect
prediction and random guessing respectively. RESULTS: The
Bayesian network was predictive of glucose and HbA1c mis-
matches in both Test Set A (AUC = 0.86 (+/-0.05)) and Test Set
B (AUC = 0.93 (+/-0.04)). Expert performance was on average
worse in Test Sets A (AUC = 0.74 (+/-0.07)) and B (AUC = 0.76
(+/-0.07)). Individual analysis revealed that the network per-
formed signiﬁcantly better (z < 1.96, p < 0.05) than 7 of the 11
experts; in no case did the network perform worse than the
experts. CONCLUSION: A Bayesian network that models
probabilistic relationships among analyte values is often better
than laboratory experts at identifying laboratory errors. This
suggests that an automated program may help reduce costs and
improve patient outcomes in the laboratory.
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OBJECTIVE: Fibrin sealants are efﬁcacious in reducing peri-
operative bleeding during a variety of surgical procedures, which
may result in decreased hospital costs and lengths of stay (LOS).
This study sought to compare hospital costs and LOS by three
ﬁbrin sealants used in cardiac surgical procedures. METHODS:
Data were extracted from a large U.S. hospital-based, service-
level comparative database. Procedures were identiﬁed using
principal ICD-9 codes. Patients who received either FloSeal®
only or one of two comparison products (Gelfoam® + thrombin
or Surgicel® + thrombin) and were discharged from hospital
between April 1, 2003 and September 30, 2006 were included.
Costs were considered from the hospital perspective and were
derived from either reported actual costs or an estimated
calculation of costs-to-charges from the Medicare Cost Report.
Regression modeling with log transformation was employed to
compare differences in ﬁxed hospital costs (those insensitive to
volume), variable costs (those sensitive to volume), and post-
operative LOS. Control variables included age, gender, All
Patient Reﬁned-Diagnosis Related Group severity codes, region,
hospital teaching status, bed size, population served (urban
or rural), and primary payer. RESULTS: A total of 35,672
discharges were included. The regression models showed that
patients who received Gelfoam + thrombin had higher ﬁxed and
variable costs (+21% and +40%, p < 0.01, respectively) and
Surgicel + thrombin had higher ﬁxed and variable costs (+18%
and +14.5%, p < 0.01, respectively) compared to FloSeal. In
terms of ﬁxed costs, this amounted to an additional $21,803 for
Gelfoam + thrombin and an additional $19,208 for Surgicel +
thrombin cohorts. In variable costs, this amounted to an
additional $26,609 for Gelfoam + thrombin and $22,181 for
Surgicel + thrombin cohorts. All three cohorts had similar post-
operative LOS. CONCLUSION: FloSeal demonstrated cost
reduction in hospital stays for cardiac procedures, compared
to two other ﬁbrin sealants. Given small margins achieved by
hospitals today, cost-effective surgical aids with better or similar
outcomes should be considered in surgical service lines.
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OBJECTIVE: Fibrin sealants are used in a variety of surgical
procedures to reduce wound bleeding. This may consequently
decrease hospital costs and lengths of stay (LOS). This study
sought to compare costs and LOS following ﬁbrin sealant use
during spinal surgery. METHODS: Data were extracted from a
largeU.S. hospital-based, service-level comparative database. Pro-
cedures were identiﬁed using principal ICD-9 codes. Patients who
received either FloSeal® only or one of two comparison products
(Gelfoam® + thrombin or Surgicel® + thrombin) and were dis-
charged from hospital between April 1, 2003 and September 30,
2006 were included. Costs were considered from the hospital
perspective and were derived from either reported actual costs or
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